Reference : Management of High Turnover Osteoporosis with Calcitonin
Scientific journals : Article
Human health sciences : General & internal medicine
Human health sciences : Rheumatology
http://hdl.handle.net/2268/125143
Management of High Turnover Osteoporosis with Calcitonin
English
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
1992
BONE
Elsevier Science
13
Suppl 2
S37-40
Yes (verified by ORBi)
International
8756-3282
1873-2763
New York
NY
[en] Osteoporosis, associated with a high turnover of bone and acute bone loss, occurs in a number of clinical models, such as following prolonged steroid therapy, extremity and spinal immobilisation, and often is associated with fracture. Confinement to bed and subsequent hypodynamism relating to the pain following a vertebral fracture may activate the process of high bone turnover and acute bone loss. In postmenopausal women, the acute bone loss resulting from such clinical pictures may be superimposed on to the natural course of bone loss occurring in many postmenopausal women. Salmon calcitonin, a potent inhibitor of osteoclast activity, has been shown to prevent bone loss in all clinical models of acute bone loss due to increased bone turnover and osteoclastic resorption. In addition, salmon calcitonin has a potent analgesic effect, thereby causing a reduction in bone pain and improvement in functional capacity. For these reasons, calcitonin remains a first-line therapy in bone loss related to a hyper-resorptive state.
http://hdl.handle.net/2268/125143
also: http://hdl.handle.net/2268/132452

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Management of high turnover osteoporosis with calcitonin.pdfPublisher postprint1.07 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.